De meeste artsen zijn ervan overtuigd dat zij duidelijk communiceren. Maar voor patiënten met verminderde gezondheidsvaardigheden valt dat best tegen. Speciaal ontwikkelde praatkaarten moeten artsen daarom helpen om moeilijke onderwerpen, zoals het … [Lees meer...] overArtsen praten nog écht te moeilijk voor patiënten met lage gezondheidsvaardig-heden
Factors Supporting a Sustainable European Biosimilar Medicines Market
A study undertaken by GfK Market Access on behalf of the European Biosimilars Group, a sector group of EGA, about the future sustainability of the biosimilar medicines market. Bron: GfK NOP Limited Lees het gehele artikel … [Lees meer...] overFactors Supporting a Sustainable European Biosimilar Medicines Market
Toelichting op standpunt biologische en biosimilar geneesmiddelen
Bron: College ter Beoordeling van Geneesmiddelen (CBG) In maart 2015 heeft het College ter Beoordeling van Geneesmiddelen (CBG) zijn standpunt over de biosimilar geneesmiddelen geactualiseerd. Op basis van reacties en gesprekken met onder andere … [Lees meer...] overToelichting op standpunt biologische en biosimilar geneesmiddelen
Biosimilars approved in the US
Last update: 14 August 2015 In the US, a legal framework for approving biosimilars was established in 2009, via the Biologics Price Competition and Innovation Act of 2009 (BPCI Act). The BPCI Act is part of the healthcare reform legislation, … [Lees meer...] overBiosimilars approved in the US
Abasaglar, Remsima, Inflectra, Hospira, Bioepis, MabThera, Herceptin & Humira
Bron: Axon Healthcare Lilly is gestart met de Europese lancering van Abasaglar (biosimilar Lantus). Ondertussen komt de uptake van Remsima en Inflectra op gang, is de overname van Hospira door Pfizer bijna afgerond en ontwikkelt Samsung Bioepis zich … [Lees meer...] overAbasaglar, Remsima, Inflectra, Hospira, Bioepis, MabThera, Herceptin & Humira
WHO issues draft proposal for its biological qualifier
The World Health Organization (WHO) first introduced the concept of a biological qualifier (BQ) for naming biologicals back in 2014. Now the body has issued a draft proposal covering the issue of how to name biologicals, including biosimilars. The … [Lees meer...] overWHO issues draft proposal for its biological qualifier
Clinical programmes for anti-TNF biosimilars
Biosimilars for anti-tumour necrosis factor (anti-TNF) drugs are currently under development. These include biosimilars of blockbusters such as AbbVie’s Humira (adalimumab), Amgen’s Enbrel (etanercept) and Johnson & Johnson’s Remicade … [Lees meer...] overClinical programmes for anti-TNF biosimilars
Phase I results for candidate adalimumab, etanercept and infliximab biosimilars
Results of phase I clinical studies of candidate adalimumab biosimilar SB5, etanercept biosimilar SB4 and infliximab biosimilar SB2, demonstrated equivalence safety profiles to their originator biologicals in healthy subjects [1-3]. The phase I, … [Lees meer...] overPhase I results for candidate adalimumab, etanercept and infliximab biosimilars
Norway, biosimilars in different funding systems
Norway has approved biosimilar versions of the biologicals somatropin, epoetin, filgrastim and infliximab. Epoetin and filgrastim are included in a national tender for drugs used in hospitals, in which prices can be reduced by up to 89%. Regional … [Lees meer...] overNorway, biosimilars in different funding systems
Volg ons via: